

ELEVATE EXCHANGE

Formulary Updates to Elevate Exchange Plans
(Bronze HDHP/Standard,
Silver Select/Standard,
Gold Select/Standard)

P&T/Formulary Committee Actions
3Q2021 (Effective October 1, 2021)

Formulary Actions Effective: 10/01/2021											Rationale of Changes			
Drug Attributes							Formulary Status		Utilization Management					
							Marketplace (HIEX)		Portfolio High / HIEX					
Category	Brand Name	Generic Name	Strength	Dosage Form	Route	Brand Status	Current Status	Action	Current Status	Action	COMMERCIAL	Optional Benefit Exclusion	Optional Non-Essential Exclusion (PFL/HIEX)	Client Communication - Commercial/HIEX
ALLERGY	RAGWITEK	WEED POLLEN-SHORT RAGWEED	12 UNIT	TAB SUBL	SUBLINGUAL	SSB	2	S=2	PA	C=PA	Clinical/Safety Strategy			
ANTIFUNGAL ANTIBIOTICS	BREXAFEMME	IBREXAFUNGERP CITRATE	150 MG	TABLET	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy			
ASTHMA AND COPD	CINQAIR	RESLIZUMAB	10 MG/ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ASTHMA AND COPD	DUPIXENT PEN	DUPILUMAB	300 MG/2ML	PEN INJCTR	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ASTHMA AND COPD	DUPIXENT SYRINGE	DUPILUMAB	300 MG/2ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ASTHMA AND COPD	DUPIXENT SYRINGE	DUPILUMAB	200MG/1.14	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ASTHMA AND COPD	FASENRA	BENRALIZUMAB	30 MG/ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ASTHMA AND COPD	NUCALA	MEPOLIZUMAB	100 MG	VIAL	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ASTHMA AND COPD	NUCALA	MEPOLIZUMAB	100 MG/ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ASTHMA AND COPD	NUCALA	MEPOLIZUMAB	100 MG/ML	AUTO INJCT	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ASTHMA AND COPD	XOLAIR	OMALIZUMAB	150 MG	VIAL	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ASTHMA AND COPD	XOLAIR	OMALIZUMAB	75MG/0.5ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ASTHMA AND COPD	XOLAIR	OMALIZUMAB	150 MG/ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
BEHAVIORAL HEALTH - OTHER	XYREM	SODIUM OXYBATE	500 MG/ML	SOLUTION	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			
BEHAVIORAL HEALTH - OTHER	XYWAV	SODIUM,CALCIUM,MAG,POT OXYBATE	0.5G/ML	SOLUTION	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			
CONTRACEPTION/OXYTOCICS	NEXTSTELLIS	DROSPIRENONE/ESTETROL	3-14.2(28)	TABLET	ORAL	SSB	3	S=3	QL	A=ST S=QL	Low Net Cost Strategy			ST: TRIAL OF TWO GENERIC ORAL CONTRACEPTIVES REQUIRED IN THE PAST 365 DAYS.
DERMATOLOGY - PSORIASIS/ECZEMA	COSENTYX PEN (2 PENS)	SECUKINUMAB	150 MG/ML	PEN INJCTR	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
DERMATOLOGY - PSORIASIS/ECZEMA	COSENTYX SYRINGE	SECUKINUMAB	150 MG/ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
DERMATOLOGY - PSORIASIS/ECZEMA	COSENTYX SYRINGE	SECUKINUMAB	75MG/0.5ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
DIABETES	ZEGALOGUE AUTOINJECTOR	DASIGLUCAGON HCL	0.6 MG/0.6	AUTO INJCT	SUBCUTANE.	SSB	3	C=2	QL ST	D=ST S=QL	Trade Relations Strategy			
DIABETES	ZEGALOGUE SYRINGE	DASIGLUCAGON HCL	0.6 MG/0.6	SYRINGE	SUBCUTANE.	SSB	3	C=2	QL ST	D=ST S=QL	Trade Relations Strategy			
DIABETES ENDOCRINE DISORDER - OTHER	MYFEMBREE	RELUGOLIX/ESTRADIOL/NORETHINDR	40-1-0.5MG	TABLET	ORAL	SSB	3	C=2	PA	C=PA	Trade Relations Strategy			
HEMATOLOGICAL DISORDERS	ULTOMIRIS	RAVULIZUMAB-CWVZ	300MG/3ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
HEMATOLOGICAL DISORDERS	ULTOMIRIS	RAVULIZUMAB-CWVZ	1100 MG/11	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
NEOPLASTIC DISEASE	AYVAKIT	AVAPRITINIB	100 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
NEOPLASTIC DISEASE	AYVAKIT	AVAPRITINIB	200 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
NEOPLASTIC DISEASE	AYVAKIT	AVAPRITINIB	300 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
NEOPLASTIC DISEASE	AYVAKIT	AVAPRITINIB	25 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			

Formulary Actions Effective: 10/01/2021												Rationale of Changes			
Drug Attributes							Formulary Status		Utilization Management						
							Marketplace (HIE)		Portfolio High / HIE						
Category	Brand Name	Generic Name	Strength	Dosage Form	Route	Brand Status	Current Status	Action	Current Status	Action	COMMERCIAL	Optional Benefit Exclusion	Optional Non-Essential Exclusion (PFL/HIE)	Client Communication - Commercial/HIE	
NEOPLASTIC DISEASE	AVVAKIT	AVAPRITINIB	50 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy				
NEOPLASTIC DISEASE	KEYTRUDA	PEMBROLIZUMAB	100MG/4ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy				
NEOPLASTIC DISEASE	OPDIVO	NIVOLUMAB	40 MG/4 ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy				
NEOPLASTIC DISEASE	OPDIVO	NIVOLUMAB	100MG/10ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy				
NEOPLASTIC DISEASE	OPDIVO	NIVOLUMAB	240MG/24ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy				
NEOPLASTIC DISEASE	TRODELVY	SACITUZUMAB GOVITECAN-HZIY	180 MG	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy				
NEOPLASTIC DISEASE	YERVOY	IPIUMUMAB	50 MG/10ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy				
NEOPLASTIC DISEASE	YERVOY	IPIUMUMAB	200MG/40ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy				
NEUROLOGICAL DISEASE - MISCELLANEOUS	ZEPOSIA	OZANIMOD HYDROCHLORIDE	0.92 MG	CAPSULE	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy				
NEUROLOGICAL DISEASE - MISCELLANEOUS	ZEPOSIA	OZANIMOD HYDROCHLORIDE	0.23-0.46	CAP DS PK	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy				
NEUROLOGICAL DISEASE - MISCELLANEOUS	ZEPOSIA	OZANIMOD HYDROCHLORIDE	0.23-0.92	CAP DS PK	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy				
OTHER DRUGS	DEFERIPRONE	DEFERIPRONE	500 MG	TABLET	ORAL	GENERIC	4	S=4	PA	C=PA	Clinical/Safety Strategy				
OTHER DRUGS	FERRIPROX	DEFERIPRONE	1000 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy				
OTHER DRUGS	FERRIPROX	DEFERIPRONE	100 MG/ML	SOLUTION	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy				
OTHER RESPIRATORY DISORDERS	TRIKAFTA	ELEXACAFTOR/TEZACAFTOR/IVACAFT	100-50-75	TABLET SEQ	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy				
OTHER RESPIRATORY DISORDERS	TRIKAFTA	ELEXACAFTOR/TEZACAFTOR/IVACAFT	50-25-37.5	TABLET SEQ	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy				
VITAMIN AND/OR MINERAL DEFICIENCY	ACCURUFER	FERRIC MALTOL	30 MG	CAPSULE	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy		FDA Approved Non-Essential		
WEIGHT REDUCTION	QSYMIA	PHENTERMINE/TOPIRAMATE	3.75-23 MG	CPMP 24HR	ORAL	SSB	3	S=3	PA	C=PA	Trade Relations Strategy	Antiobesity			
WEIGHT REDUCTION	QSYMIA	PHENTERMINE/TOPIRAMATE	7.5MG-46MG	CPMP 24HR	ORAL	SSB	3	S=3	PA	C=PA	Trade Relations Strategy	Antiobesity			
WEIGHT REDUCTION	QSYMIA	PHENTERMINE/TOPIRAMATE	15 MG-92MG	CPMP 24HR	ORAL	SSB	3	S=3	PA	C=PA	Trade Relations Strategy	Antiobesity			
WEIGHT REDUCTION	QSYMIA	PHENTERMINE/TOPIRAMATE	11.25-69MG	CPMP 24HR	ORAL	SSB	3	S=3	PA	C=PA	Trade Relations Strategy	Antiobesity			
WEIGHT REDUCTION	WEGOVY	SEMAGLUTIDE	0.25MG/0.5	PEN INJCTR	SUBCUTANE.	SSB	3	C=2	PA	C=PA	Trade Relations Strategy	Antiobesity			
WEIGHT REDUCTION	WEGOVY	SEMAGLUTIDE	0.5MG/.5ML	PEN INJCTR	SUBCUTANE.	SSB	3	C=2	PA	C=PA	Trade Relations Strategy	Antiobesity			
WEIGHT REDUCTION	WEGOVY	SEMAGLUTIDE	1MG/0.5ML	PEN INJCTR	SUBCUTANE.	SSB	3	C=2	PA	C=PA	Trade Relations Strategy	Antiobesity			
WEIGHT REDUCTION	WEGOVY	SEMAGLUTIDE	1.7MG/0.75	PEN INJCTR	SUBCUTANE.	SSB	3	C=2	PA	C=PA	Trade Relations Strategy	Antiobesity			
WEIGHT REDUCTION	WEGOVY	SEMAGLUTIDE	2.4MG/0.75	PEN INJCTR	SUBCUTANE.	SSB	3	C=2	PA	C=PA	Trade Relations Strategy	Antiobesity			

MedImpact Managed Formulary Actions

RATIONALE OF CHANGES

Trade Relations Strategy

Approach based on a financial review to deliver low net cost opportunities through pharmaceutical manufacture agreement strategies while taking into consideration the expected market share shift, future pipeline products, member impact and plan impact.

Low Net Cost Strategy

Delivering cost-efficient and clinically appropriate formulary content to meet the pharmacy benefit management needs of MedImpact clients; including appropriate development of preferred drug lists with consideration of low net cost strategies that includes MAC lists, non-pharmaceutical manufacture agreement strategies, and other cost management tools.

Clinical/Safety Strategy

Delivering cost-efficient and clinically appropriate formulary content to promote member safety and savings through the evaluation of scientific evidence, standards of practice, peer-reviewed medical literature, clinical practice guidelines, and guidance from the U.S. Food and Drug Administration (FDA)/Center for Disease Control (CDC).

Regulatory Update

Formulary/utilization management changes to comply with federal and/or state statutes, regulations, rules and policy requirements that pertain to the administration of the pharmacy benefit.

LEGEND

Note: The drug names listed are for reference purposes and denote action on the chemical entity unless otherwise specified. Where generic and brand products for a chemical entity co-exist, coverage and copayment for each will be a function of plan benefit design.

FORMULARY		UTILIZATION MANAGEMENT (UM)		OPTIONAL BENEFIT EXCLUSION
Formulary Status	Formulary Actions	UM Definition	UM Actions	Coverage for each category will be a function of plan benefit design. These products may be excluded on client benefits. Formulary and UM decisions only apply for clients who choose to provide coverage for these drug categories.
F = Formulary	C = Change	AGE = Age restriction	A = Add UM	Antiobesity
NF = Non-Formulary	S = Sustain	QL = Quantity Limit	D = Delete UM	Cosmetic Indications
E = Excluded		ST = Step Therapy	C = Change UM	Dietary Supplements and Non-Drug Products
NC = Not covered		CU = Concurrent Use edit	E = Excluded drug from formulary	Erectile Dysfunction
		PA = Prior Authorization	S = Sustain UM	Infertility
		HST= Hard Step (Step without grandfathering-member must try preferred agents)		Medical Foods: Dietary supplements, Enteral Feeding, Infant formula
				Non-Self Administered Drug (NSA)
				Ostomy Supplies
				Class O = Over the Counter Products
				Class Q = Products that are neither drugs nor devices, such as dietary supplements (including prenatal and other vitamins), medical foods, herbal preparations, and bulk flavorings or colorants